{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:18Z","timestamp":1791281718685,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5428,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.nurt.2008.08.009","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T15:11:21Z","timestamp":1223133081000},"page":"569-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Therapeutic Approaches in Glycogen Storage Disease Type II\/Pompe Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Benedikt","family":"Schoser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.08.009_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib2","series-title":"Myology","first-page":"1559","article-title":"Acid maltase deficiency","author":"Engel","year":"2003"},{"key":"10.1016\/j.nurt.2008.08.009_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.08.009_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.nurt.2008.08.009_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02889851","article-title":"Infantile acid maltase deficiency","volume":"45","author":"Griffin","year":"1984","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.nurt.2008.08.009_bib6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.nurt.2008.08.009_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.08.009_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"key":"10.1016\/j.nurt.2008.08.009_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nurt.2008.08.009_bib11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.08.009_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","article-title":"Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors","volume":"61","author":"Kornfeld","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.nurt.2008.08.009_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.nurt.2008.08.009_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.169.3941.141","article-title":"Inborn errors of mucopolysaccharide metabolism","volume":"169","author":"Neufeld","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.08.009_bib15","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.08.009_bib16","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.08.009_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.08.009_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1010383421286","article-title":"Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk","volume":"24","author":"Van den Hout","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nurt.2008.08.009_bib19","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.nurt.2008.08.009_bib20","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"10.1016\/j.nurt.2008.08.009_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.nurt.2008.08.009_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.nurt.2008.08.009_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.08.009_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.009_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.009_bib26","unstructured":"van Capelle CI, Winkel LPF, Hagemans MLC, et al. Paper presented at: Fifth Symposium on Lysosomal Storage Disorders; April 10\u201312, 2008; Paris, France."},{"key":"10.1016\/j.nurt.2008.08.009_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073807302598","article-title":"Long-term enzyme replacement therapy for Pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells","volume":"22","author":"Rossi","year":"2007","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.nurt.2008.08.009_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022998010833","article-title":"Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice","volume":"12","author":"Raben","year":"2003","journal-title":"Transgenic Res"},{"key":"10.1016\/j.nurt.2008.08.009_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/mus.20896","article-title":"Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease","volume":"37","author":"Drost","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.08.009_bib30","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1089\/hum.1997.8.13-1555","article-title":"Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion","volume":"8","author":"Zaretsky","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/hmg\/7.11.1695","article-title":"Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation","volume":"7","author":"Nicolino","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/104303401300042447","article-title":"Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease","volume":"12","author":"Pauly","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol Ther"},{"issue":"5 Pt 1","key":"10.1016\/j.nurt.2008.08.009_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","article-title":"Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy","volume":"10","author":"Raben","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","article-title":"Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme","volume":"6","author":"Raben","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/hmg\/11.14.1637","article-title":"Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy","volume":"11","author":"Martin-Touaux","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib39","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.08.009_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jgm.660","article-title":"Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA","volume":"7","author":"Xu","year":"2005","journal-title":"J Gene Med"},{"key":"10.1016\/j.nurt.2008.08.009_bib41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/104303401750195917","article-title":"Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type ii knockout mice","volume":"12","author":"Ding","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib42","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.gt.3302314","article-title":"Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model","volume":"11","author":"Xu","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/hum.2005.16.68","article-title":"Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II","volume":"16","author":"Cresawn","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1525-0016(03)00022-4","article-title":"Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1525-0016(02)00055-2","article-title":"Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymthe.2005.08.006","article-title":"Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice","volume":"13","author":"Kiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib49","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib50","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.nurt.2008.08.009_bib51","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.gt.3302550","article-title":"Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors","volume":"12","author":"Mah","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib53","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jgm.581","article-title":"Gene therapy for lysosomal storage diseases: the lessons and promise of animal models","volume":"6","author":"Ellinwood","year":"2004","journal-title":"J Gene Med"},{"key":"10.1016\/j.nurt.2008.08.009_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10545-007-0519-9","article-title":"Glycogen storage disease types I and II: treatment updates","volume":"30","author":"Koeberl","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nurt.2008.08.009_bib56","first-page":"49","article-title":"Progress and problems when considering gene therapy for GSD-II","volume":"26","author":"Kiang","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.nurt.2008.08.009_bib57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ymgme.2007.04.018","article-title":"Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease","volume":"91","author":"Hawes","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nurt.2008.08.009_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-006-0280-4","article-title":"New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy","volume":"121","author":"Beck","year":"2007","journal-title":"Hum Genet"},{"key":"10.1016\/j.nurt.2008.08.009_bib59","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.08.009_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nurt.2008.08.009_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cca.2008.02.014","article-title":"Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism","volume":"391","author":"Yoshimizu","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nurt.2008.08.009_bib62","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.febslet.2006.06.096","article-title":"Stabilising normal and mis-sense variant alpha-glucosidase","volume":"580","author":"Kakavanos","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nurt.2008.08.009_bib63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodeled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.nurt.2008.08.009_bib64","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bbrc.2006.09.133","article-title":"Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy","volume":"350","author":"Matalon","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nurt.2008.08.009_bib65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1212\/WNL.33.1.34","article-title":"Improvement of muscle function in acid maltase deficiency by high-protein therapy","volume":"33","author":"Slonim","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.009_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.20665","article-title":"Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy","volume":"35","author":"Slonim","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.08.009_bib67","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mus.20473","article-title":"Benign course of glycogen storage disease type IIb in two brothers: nature or nurture?","volume":"33","author":"Slonim","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.08.009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:39:20Z","timestamp":1761806360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1878747923004634"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.009","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Approaches in Glycogen Storage Disease Type II\/Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}